Skip to Content

Join the 'Exjade' group to help and get support from people like you.

Exjade News

FDA Approves Jadenu (deferasirox) Tablets for Chronic Iron Overload

Posted 30 Mar 2015 by Drugs.com

Basel, March 30, 2015 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu (deferasirox) tablets, a new oral formulation of Exjade (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes ...

FDA Approves Exjade to Remove Excess Iron in Patients with Genetic Blood Disorder

Posted 23 Jan 2013 by Drugs.com

January 23, 2013 – The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT). NTDT is a milder form of thalassemia that does not require individuals to get frequent red blood cell transfusions. ...

Exjade Approved for Inherited Blood Disorder

Posted 23 Jan 2013 by Drugs.com

WEDNESDAY, Jan. 23 – Exjade (deferasirox) has been approved by the U.S. Food and Drug Administration to remove excess iron in the blood among people with a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT). Too much iron in the blood can damage vital organs, the agency said Wednesday in a news release. Thalassemia typically leads to the production of fewer red blood ...

FDA Medwatch Alert: Exjade (deferasirox)

Posted 13 Dec 2007 by Drugs.com

[UPDATE 12/13/2007] Novartis informed healthcare professionals of changes made to the WARNINGS, ADVERSE REACTIONS, and DOSAGE and ADMINISTRATION sections of prescribing information for Exjade Tablets for Oral Suspension. The WARNINGS and ADVERSE REACTIONS sections of the labeling were revised to include information about postmarketing reports of hepatic failure, some with a fatal outcome, in ...

FDA Medwatch Alert: Exjade (deferasorix) Tablets For Oral Suspension

Posted 22 May 2007 by Drugs.com

[Posted 05/22/2007] Novartis and FDA notified healthcare professionals of changes to the WARNINGS and ADVERSE REACTIONS sections of the product labeling for Exjade, a drug used to treat chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. Cases of acute renal failure, some with a fatal outcome, have been reported following the post ...

Ask a Question

Further Information

Related Condition Support Groups

Iron Overload, Thalassemia, Hemosiderosis

Exjade Patient Information at Drugs.com